Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Alector, Inc. (ALEC)

1.7500 +0.1900 (+12.18%)
As of June 18 at 4:00:00 PM EDT. Market Open.
Trade Alector on Coinbase
Chart Range Bar
Loading chart for ALEC
  • Previous Close 1.5600
  • Open 1.5800
  • Bid 1.2600 x 200
  • Ask 2.0300 x 200
  • Day's Range 1.5650 - 1.7650
  • 52 Week Range 1.0900 - 3.4000
  • Volume 1,108,200
  • Avg. Volume 662,092
  • Market Cap (intraday) 194.294M
  • Beta (5Y Monthly) 0.59
  • PE Ratio (TTM) --
  • EPS (TTM) -1.1900
  • Earnings Date (est.) May 11, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.10

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

www.alector.com

103

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 6/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ALEC
12.18%
S&P 500 (^GSPC)
9.57%

1-Year Return

ALEC
19.86%
S&P 500 (^GSPC)
25.41%

3-Year Return

ALEC
76.57%
S&P 500 (^GSPC)
70.10%

5-Year Return

ALEC
91.76%
S&P 500 (^GSPC)
80.02%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 1.05M
Earnings -22.93M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-30M
-20M
-10M
0

Analyst Insights

View More

Analyst Price Targets

1.00 Low
3.10 Average
1.7500 Current
6.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/15/2026
Analyst Cantor Fitzgerald
Rating Action Upgrade
Rating Overweight
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
As of 6/18/2026
  • Market Cap

    194.29M

  • Enterprise Value

    22.33M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.05

  • Price/Book (mrq)

    18.71

  • Enterprise Value/Revenue

    1.21

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -25.71%

  • Return on Equity (ttm)

    -238.85%

  • Revenue (ttm)

    18.42M

  • Net Income Avi to Common (ttm)

    -125.39M

  • Diluted EPS (ttm)

    -1.1900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    206.52M

  • Total Debt/Equity (mrq)

    332.77%

  • Levered Free Cash Flow (ttm)

    -119.11M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.7500 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: